FDA Grants Expanded Access Program to Ulixertinib for MAPK Pathway Aberrant Cancer
September 29, 2020 3:00 pmBy Matthew Fowler
xCures recently announced that the FDA granted its IND immediate Expanded Access Program for the ERK inhibitor ulixertinib to treat patients with MAPK pathway aberrant cancer.
The FDA granted the investigational new drug application for the ERK